title: Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.
abstract: ► Bevacizumab may increase the risk of mucosal ulceration and subsequent bone necrosis. ► Patients receiving bevacizumab should be closely monitored for dental symptoms.
authors.affiliation: Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA.
authors.forename: Deanna
authors.initials: D
authors.lastname: Teoh
authors.affiliation: Preston Oral-Maxillofacial Surgery, Cary, NC 27513, USA.
authors.forename: John S
authors.initials: JS
authors.lastname: Won
authors.affiliation: Atlantic Family Dental, Raleigh, NC 27604, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Eisberg
authors.affiliation: Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Nolte
authors.affiliation: Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA.
authors.forename: Angeles Alvarez
authors.initials: AA
authors.lastname: Secord
keywords: Bevacizumab; Ovarian cancer